IMCR IMCR
Company Profile ↓Company Overview
IMCR (IMCR) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 214.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $400.02M (+29.0% YoY); net profit $-35.51M.
- Trailing 12 Months Year-on-year growth — revenue +28.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 214.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 214.71% |
| 1 Year: | 28.95% |
Stock Price Performance
| 1 Year: | +2.34% |
| 6 Months: | +3.80% |
| 3 Months: | +15.43% |
| 1 Month: | -0.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 214.7% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 70.50M | 75.40M | 80.25M | 93.88M | 97.96M | 103.69M | 106.68M |
| Operating Income | -14.70M | -13.76M | -14.14M | -26.49M | -16.02M | -8.50M | -3.62M | -14.88M | -7.17M | 7.28M |
| Net Income | -19.45M | -17.01M | 906.00K | -24.44M | -11.62M | 8.74M | 5.02M | -10.30M | -177.00K | 12.97M |
| Diluted EPS | -0.40 | -0.35 | 0.02 | -0.49 | -0.23 | 0.17 | 0.10 | -0.20 | 0.00 | 0.25 |
| R&D Expense | 36.57M | 38.16M | 43.25M | 57.46M | 51.07M | 52.77M | 56.47M | 69.01M | 70.57M | 61.11M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.08M | 174.36M | 249.43M | 310.20M | 400.02M |
| Operating Income | -174.59M | -51.71M | -59.65M | -70.46M | -45.35M |
| Net Income | -180.03M | -52.54M | -55.29M | -51.09M | -35.51M |
| Diluted EPS | -4.24 | -1.15 | -1.13 | -1.02 | -0.71 |
| R&D Expense | 100.25M | 101.92M | 163.54M | 222.15M | 274.87M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 526.76M | 597.00M | 1.01B | 1.07B |
| Total Equity | 76.91M | 233.71M | 338.90M | 368.84M | 360.72M | 381.03M |
| Cash & Equivalents | - | - | 402.47M | 442.63M | 455.73M | 467.71M |
| Total Liabilities | - | - | 187.86M | 228.16M | 648.79M | 686.24M |
| Current Liabilities | - | - | 100.83M | 139.02M | 212.18M | 246.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -143.11M | -49.21M | 2.94M | 26.06M | -10.71M |
| Investing Cash Flow | -1.28M | -2.20M | -5.42M | -355.13M | -16.34M |
| Financing Cash Flow | 288.19M | 145.44M | 34.35M | 343.88M | 12.37M |
| Capital Expenditure | -1.39M | -2.20M | -5.42M | -5.17M | -4.34M |
| Free Cash Flow | -144.49M | -51.41M | -2.48M | 20.89M | -15.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | -4,281.2% | -29.7% | -23.9% | -22.7% | -11.3% |
| Net Margin % | -4,414.6% | -30.1% | -22.2% | -16.5% | -8.9% |
| ROE % | -77.0% | -15.5% | -15.0% | -14.2% | -9.3% |
| ROCE % | - | -12.1% | -13.0% | -8.8% | -5.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMCR
Immunocore Holdings (IMCR) Stock Could Be 57% Below Fair Value After Recent Weakness - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQR2h3NUcyRlRDeUx4UWlMTDRuTEpRT1R6eVBRSlRZdlEwaThremIwOWpBZkE5aU9JSHA0WHUwcUlVV1B1VUE5dE80TmhHSjVlS0FkbHBIV2Y0cWgtSlNEeG4zSFA3SFNkTWd5MEY3Vi1wYnVqWThZajlNaE9DVTEwM19LRVd1bTZwY055cW…
IMCR Maintained by Mizuho -- Price Target Raised to $35.00 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQekJWcU53c0VuU3lZMmpaNnRNRTJkN19mNmU4WUtLNkctSW1rOUUxdk1yOWZaUXNBeV9MT25YbzNaVlZoMWQtcVZuZ3did3dHWkVzVjV1dm54cjEwZHNjVFg2N1BuajdyMEJpM1FhSkRZaWtwR09TWjhIRmpmUk1mSVVwVlFtbW51V0NPS1…
Immunocore to Detail Its Business and Portfolio on Aug. 6 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPOVBLOE5BcGNtaFVacHNqbWJocVM3ZUM1X1AtTGRKSk1jbDNoczdzR3F3WHEtYXdHM0laRHRqLUpxc2pNQWJRUjdvMUF6Njk4aVNabzRyV1NnUEJIZy1OYS10NlQwQjF0VWZibVZUelg5dnBWRHdBTEFpck5hQVEzdjdkdGphMWkySEVkS2…
Trading the Move, Not the Narrative: (IMCR) Edition - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNdW1KTTBCSlR6b2pXcXNqNFVIdFplV19GN3lfTTc2ZTNCRWZrUHlSRTJTbkRPRjFzd3VFWVVCclV6Ry1pcWxzZ0JXSTdwaFRoU0dTVjBYWUxXOFg2Y1ZxZFdhUkhnMmplSXRYZVN1WUp4LXR1a3lCdkZFRWJ5cDdtajlNODhCdUV1R0w0cF…
Immunocore (IMCR) Stock May Trade Above Fair Value On A 48% Slump - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQNFFKY2FQLXo4bFBEZERNTUduUDFhQkRpbUhCNXNEVnZoOVpGMU40Yjl3OV9lV2NIa2luUHU5Rk1CWFdqcnNyb0tkWS1jWm5lbWR2VWlGV1o4U215bHRaal9iSjM5OHkySVpzdm5ySlBReDluY3Y3VGJ1QlVZMzhGQ2p4UTVzWjctYUVKZD…
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth? - TradingView
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQN2c3SGxTVjNBd0xJZnhWX29MVm5mWEZkWFcxMEowSGx3NUhXRjUwaUNFVmE5UDRXNlMzeUhhWWtmTkg4YVpsQ2pUWXFiTFU1cjc3SlJJNGVuUjk5SFVZRzJLSlNxMGF3MDMtX2Z4ZmJRZUhTN1ZhSWhvN1pmZGdCY1RyMWg1bXlHeFNuaG…
IMCR — Frequently Asked Questions
What is the current share price of IMCR?
As of 2026-08-05 17:25 PDT, IMCR trades at $33.29 on NASDAQ/NYSE. Its 52-week range is $27.79 to $40.22.
What is the P/E ratio of IMCR?
IMCR trades at a trailing price-to-earnings (P/E) ratio of -46.89.
What is the return on equity (ROE) of IMCR?
IMCR has a return on equity (ROE) of -9.32%. Its return on capital employed (ROCE) is -5.53%.
Is IMCR a good stock to buy?
This page provides a data-driven analysis of IMCR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.